{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["UCART19"]],"indication":"paediatric relapsed/refractory B-cell acute lymphoblastic leukemia","name":"PALL","nct_id":"NCT02808442","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pall-nct02808442. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PALL","arms":[{"description":null,"label":"UCART19","type":"EXPERIMENTAL"}],"collaborators":["ADIR, a Servier Group company"],"completion_date":{"date":"2020-11-04","type":"ACTUAL"},"conditions":["Refractory B-cell Acute Lymphoblastic Leukemia","Relapsed B-cell Acute Lymphoblastic Leukemia"],"enrollment":{"count":13,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"UCART19","otherNames":["S68587"],"type":"BIOLOGICAL"}],"last_update":"2021-10-08","lead_sponsor":"Institut de Recherches Internationales Servier","official_title":"A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2020-09-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Incidence and Severity of Adverse Events","timeFrame":"From inclusion to Month 12"}],"references":[{"citation":"Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W; UCART19 Group. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5.","pmid":"33308471","type":"RESULT"},{"citation":"Li YR, Zhu Y, Fang Y, Lyu Z, Yang L. Emerging trends in clinical allogeneic CAR cell therapy. Med. 2025 Aug 8;6(8):100677. doi: 10.1016/j.medj.2025.100677. Epub 2025 May 13.","pmid":"40367950","type":"DERIVED"}],"start_date":{"date":"2016-06-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia","url":"https://clinicaltrials.gov/study/NCT02808442"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pall-nct02808442"}